D-0319-2024 Class II Terminated

Recalled by Amneal Pharmaceuticals Of New York, LLC — Brookhaven, NY

FDA drug recall D-0319-2024 was initiated by Amneal Pharmaceuticals Of New York, LLC on Jan 15, 2024 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Out of specification for unknown impurity. The recall status is terminated (terminated Jan 31, 2025). Affected quantity: 858 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 14, 2024
Initiation Date
Jan 15, 2024
Termination Date
Jan 31, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
858 bottles

Product description

Phenoxybenzamine Hydrochloride Capsules, USP 10mg, 100-count bottle, Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd, Oral Solid Dosage Unit, Ahmedabad 382213, India, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807, NDC 60219-1502-01

Reason for recall

Failed Impurities/Degradation Specifications: Out of specification for unknown impurity.

Distribution pattern

USA nationwide.

Code information

Lot # AM221153, Exp. date 06/30/2024; AM230497, Exp. date 02/29/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0319-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0319-2024. Report a data issue: hello@regdatalab.com.